Brief: Tango Therapeutics Announces First Patient Dosed In TNG260 Phase 1/2 Trial In Patients With STK11-Mutant Cancers
24/07/2023 12:08
July 24 (Reuters) - Tango Therapeutics Inc TNGX.O :
* TANGO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TNG260
PHASE
1/2 TRIAL IN PATIENTS WITH STK11-MUTANT CANCERS
Source text for Eikon: ID:nGNX2LcfZY
Further company coverage: TNGX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tango Therapeutics
See all newsBrief: Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities
Brief: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tango Therapeutics - Files Prospectus To Sell Up To $400 Million In Common Stock
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,